Intravitreal Fasudil combined with bevacizumab for treatment of refractory diabetic macular edema; a pilot study

Ramin Nourinia, Hamid Ahmadieh, Mohammad Hassan Shahheidari, Souska Zandi, Shintaro Nakao, Ali Hafezi-Moghadam

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: To evaluate the effect of intravitreal injection of a Rho-associated protein kinase (ROCK) inhibitor (Fasudil, Asahi Kasei Pharma Corporation, Tokyo, Japan) combined with intravitreal bevacizumab (IVB) on refractory diabetic macular edema (DME). Methods: This prospective, interventional case series included 15 eyes of 15 patients with DME unresponsive to previous IVB injections. Eligible eyes underwent intravitreal injection of 0.025 mg Fasudil and 1.25 mg bevacizumab. Best corrected visual acuity (BCVA) and central macular thickness (CMT) were evaluated before and 4 weeks after treatment. Results: Mean age was 64.6±7.3 (range, 49-79) years and mean number of previous IVB injections was 2.8. Mean pre-injection BCVA was 0.84±0.35 LogMAR, which was improved to 0.49±0.29 LogMAR four weeks after intervention (P=0.003). Mean CMT was decreased from 448±123 μm before treatment, to 347±76 μm at four weeks (P=0.001); no adverse event was observed during the study period. Conclusion: Intravitreal ROCK inhibitors seem to entail structural and visual benefits in eyes with DME refractory to IVB monotherapy.

Original languageEnglish
Pages (from-to)337-340
Number of pages4
JournalJournal of Ophthalmic and Vision Research
Volume8
Issue number4
Publication statusPublished - Dec 1 2013
Externally publishedYes

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Nourinia, R., Ahmadieh, H., Shahheidari, M. H., Zandi, S., Nakao, S., & Hafezi-Moghadam, A. (2013). Intravitreal Fasudil combined with bevacizumab for treatment of refractory diabetic macular edema; a pilot study. Journal of Ophthalmic and Vision Research, 8(4), 337-340.